Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf bronchoalveolar lavage in adult pulmonary contusion at risk of ALI/ARDS
2006-002550-30Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of Poractant alfa in Lung Contusion, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Duration of intubation. Started Oct 2006; status: completed.
02
Drugs
Poractant alfa
03
Conditions
Lung Contusionacute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2006-002550-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002550-30.